Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. Some patients with HCC are diagnosed with macrovascular invasion (MVI), which is associated with a poorer prognosis. In Taiwan, sorafenib is the first-line therapy for patients with advanced HCC. However, the ef...
Main Authors: | Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Cheng-Yuan Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/30/12/737 |
Similar Items
-
Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
by: Meng-Chuan Lu, et al.
Published: (2023-05-01) -
Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib
by: Lujun Shen, et al.
Published: (2018-12-01) -
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
by: Hsu CH, et al.
Published: (2014-06-01) -
Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
by: Liming Zheng, et al.
Published: (2021-11-01) -
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)